Welcome to Chemren.com!Help Center 中文 Sign upLogin
Post Information
Products Suppliers Technologies Group Buying Surplus
Organic Raw Materials
Hydrocarbon Compounds Alcohols、Phenols、Ethers Aldehydes、Ketones、Quinones Esters Carboxylic Acids Halides Aromatic Compounds Heterocyclic Compounds Amino Acids、Proteins、Nucleic Acids Nitrogenous Organic Compounds Nitrogenous Organic Compounds Phosphorated Organic Compounds Sulfurated Organic Compounds Other Elemental Organic Compounds Organic Salts Carbohydrates Others
Organic Intermediates
Synthetic Intermediates Other Intermediates
Biochemicals and Pharmaceutical Chemicals
APIs Pharmaceutical Intermediates Biological Products Pharmaceutical Excipients Veterinary Drugs Finished Dosage Forms Pharmaceutical Impurities
Pesticides Fertilizers Pesticide Intermediates Others
Food and Feed Additives
Food Additives Feed Additives
Flavors and Fragrances
Flavors and Essences Spices Flavor and Fragrance Intermediates
Dyes and Pigments
Dyes Pigments Dye Intermediates
Catalysts and Additives
Additives and Auxiliaries Catalysts
Coatings and Paints
Coatings Paints Inks Others
Organic Adhesives Inorganic Adhesives
Inorganic Chemicals
Inorganic Salts Inorganic Acids Inorganic Alkalines Inorganic Oxides Elements Halides Others
Natural Products and Extracts
Plant Extracts Herbal Extracts Natural Products
Material Chemicals
Polymer Materials Metal and Ceramic Materials Nanomaterials
Electronic Chemicals
OFET Materials Electrode Materials Liquid Crystals
Household Chemicals
Cosmetics Oral Care Chemicals Skin Care Chemicals Household Insecticides Detergent Chemicals
Heat Exchange Equipment Reaction Equipment Crushing Equipment Mixing Equipment Separation Equipment Pressure Vessel Refrigeration Equipment Mass Transfer Equipment Molding Equipment Storage/Transport Equipment Drying Equipment Green Facilities Pump/Valve Equipment Conveying Equipment Instrumentation Auxiliary Equipment Crystallization Equipment Seal Machinery Heating Equipment Other Chemical Equipment
Other Chemicals
Other Chemicals
Location:Home > News Detail

AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal

Last Update:2019-04-15   |   Comments:0 A+ A-

Brief:After AbbVie walked away from its proposed Shire buy, Shire investors said AbbVie never disclosed its true intentions—avoiding U.S. taxes by moving its official headquarters to Ireland. Now, the sides have agreed to settle their legal fight.

AbbVie agreed to settle with Shire investors over its abandoned tax inversion, a court filing shows. (AbbVie)

After AbbVie walked away from its proposed Shire buy, Shire investors said AbbVie never disclosed its true intentions—avoiding U.S. taxes by moving its official headquarters to Ireland. Now, the sides have agreed to settle their legal fight.


Shire since sold itself to Takeda for $62 billion. But back in 2014, AbbVie and Shire were planning their own megamerger in a deal that would have moved the U.S. drugmaker's official headquarters to Ireland and dramatically cut its tax bill.


It was one in a series of biopharma tax inversions—or attempted inversions—including Pfizer's proposed-and-abandoned Allergan buyout. But just as the ink was drying on AbbVie's Shire agreement, public and political pressure swelled against the tax-avoiding deals. Then-President Barack Obama, U.S. lawmakers and others blasted inversions as “unpatriotic,” Shire investors wrote in their lawsuit against AbbVie. The U.S. Department of the Treasury ultimately changed its rules to discourage inversions, and AbbVie walked away from its Shire pursuit. 


After AbbVie pulled out, Shire investors said AbbVie was never upfront about its intentions. For instance, on one July 2014 conference call, AbbVie CEO Richard Gonzalez said tax benefits were “not the primary rationale” for the combination, the suit said. “We would not be doing it if it was just for the tax impact," Gonzalez maintained.


RELATED: AbbVie calls it quits on $55B Shire takeover 

But AbbVie reversed course after the Treasury changed the rules governing inversions. The changes removed “fundamental financial benefits of the transaction,” AbbVie said, according to the suit. Fortune Magazine called Gonzalez’s statements about the merger “outright deceit.” 


In its response to the suit in court, AbbVie denied many of the plaintiffs’ allegations. The drugmaker said it “repeatedly disclosed that tax benefits were one factor among a number of factors” supporting the proposed Shire deal.


Now, the sides have struck an agreement in principle to settle the allegations, according to a new filing in federal court in the Northern District of Illinois. The parties plan to file "a motion for preliminary approval of the settlement within the next few weeks," the filing says. The entry didn't disclose a dollar amount. AbbVie didn’t immediately respond to a request for comment. 


RELATED: AbbVie's Humira antitrust woes snowball as class-action plaintiffs pile in 

The biopharma landscape has changed dramatically since AbbVie and Shire discontinued their deal talks. Shire has since sold to Takeda for $62 billion, creating a leading biopharma company. AbbVie later scooped up Pharmacylics for $21 billion, getting half of the rights to Imbruvica, a rising star in the oncology world that last year generated $3.59 billion for the Illinois drugmaker.


And AbbVie ended up not needing the inversion, after all. Thanks to new tax changes pushed by President Donald Trump, the company last year paid an adjusted tax rate of 8.7%.


Now, AbbVie is working to diversify beyond the world’s bestselling drug, Humira. As it works to grow sales for other meds, AbbVie’s defense strategy for Humira has caught criticism. The company has inked numerous settlements with biosimilar companies for 2023 launches in the U.S. even as copycats have hit the market in Europe. Critics have said the company’s “patent thicket” around Humira is anticompetitive.


About Us
Contact Us
User Agreement
Privacy Policy
Resource Docking
Offline Activities
Technical Services
Sales Promotion
Update Info
Retrieve Password
Sign Up
User Center
Product Presales
Technology Purchase
Technology Transfer
Sell Products